Pulmospheres — tiny, three-dimensional spheres made of lung cells taken from patients — can predict how well a person with idiopathic pulmonary fibrosis (IPF)…
Articles by Joana Fernandes, PhD
European patients with idiopathic pulmonary fibrosis (IPF) have lengthy and costly hospital stays, mainly because of acute respiratory events, according to a new…
Evotec and MaRS Innovation have teamed to launch Fibrocor Therapeutics, a pharmaceutical company that will be dedicated to…
The prognosis for older idiopathic pulmonary fibrosis (IPF) patients was the same as that of younger ones in a recent study…
Promedior, a biotechnology company that focuses on anti-tissue-scarring therapies, has lined up the patients it needs for two Phase 2…
Treatment with PBI-4050 may be a safe and effective therapy for patients with idiopathic pulmonary fibrosis (IPF), according to…
Patients with idiopathic pulmonary fibrosis (IPF) have a high risk of developing other health conditions, according to results of a…
Esbriet (pirfenidone) can be used as a long-term therapy in idiopathic pulmonary fibrosis (IPF) patients with more severe loss of…
The National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH) awarded a seven-year grant worth $5.2…
Although the immune system works to fight pathological agents that invade the body, preventing disease, certain immune cells respond in ways that…